K filing that it received a letter from the staff of the Securities and Exchange Commission’s Division of Enforcement in ...

Hims & Hers Health is facing existential risk as regulatory uncertainty and margin erosion undermine its growth narrative. Click here to read why HIMS is a Sell.

The telehealth platform logged a quarterly profit of $20.6 million as it worked to offer a wider range of treatments and grew ...

Hims & Hers Health, Inc., faces GLP-1 headwinds, volatility, and regulatory risk but has strong revenue growth and global ...

Hims & Hers Health has a lower P/E than the aggregate P/E of 84.35 of the Health Care Providers & Services industry. Ideally, one might believe that the stock might perform worse than its peers, but ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Hims & Hers Health, Inc. (HIMS) reports results for the quarter ended September 2025. While this widely-known ...

By Nell Mackenzie and Samuel Indyk LONDON, Feb 13 (Reuters) - Hedge fund bets against Hims & Hers Health hit their highest in ...

Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term losses from the stock lately, despite its bumpy ride over recent months. The San Francisco, CA-based health and ...

Financial giants have made a conspicuous bullish move on Hims & Hers Health. Our analysis of options history for Hims & Hers Health (NYSE:HIMS) revealed 13 unusual trades. Delving into the details, we ...